$CVS

5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns

The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, ODP, STNE and PSFE are some such stocks.

Original reporting
Zacks Commentary · Kinjel Shah
Published Jul 2, 2025, 12:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns — source image
Decision brief

The 30-second read

$CVSBullishMed
01

Why it matters

If market conditions remain stable, these stocks could outperform broader indices; however, risks include market corrections and sector downturns.

02

Market read

The stocks discussed are primarily relevant within the US retail, healthcare, and financial sectors, with moderate impact on overall market sentiment.

03

What to watch

Market-wide valuation corrections, sector-specific headwinds, or macroeconomic shifts could negate potential gains from these stocks.

Timing: Short to medium term (1-3 months)

Background

The article highlights stocks with low Price-to-Book ratios that may be undervalued and have high growth prospects.

Company-level read

Ticker impact

$CVSBullishMedium confidence
Context

High relevance due to positive sentiment and industry significance.

Expected impact

Moderate increase in stock price over the next 1-3 months.

Evidence & confidence

The positive sentiment and low P/B ratio suggest undervaluation with growth potential, but market conditions and company-specific factors introduce uncertainty.

$PSFEBullishMedium confidence
Context

Moderate relevance; sentiment indicates some bullish outlook but lower industry impact.

Expected impact

Potential for slight upward movement in the near term.

Evidence & confidence

While sentiment is positive, lower relevance and industry factors suggest limited impact on overall trading strategies.

$CNCBullishMedium confidence
Context

Moderate relevance; similar to other stocks with positive sentiment and growth prospects.

Expected impact

Likely moderate price appreciation in upcoming weeks.

Evidence & confidence

The stock's low P/B ratio and positive sentiment support potential gains, but external factors may influence outcomes.

$STNEBullishMedium confidence
Context

Moderate relevance; somewhat bullish sentiment with growth potential.

Expected impact

Potential for upward movement in the near future.

Evidence & confidence

Positive sentiment and industry relevance support this outlook, though external factors may influence results.

Market effects

Potential positive impact on retail, healthcare, and financial sectors due to undervaluation signals.

Limited regional impact; focus is primarily on US-based stocks.

Low; these stocks are primarily US-focused with limited global influence.

Counterpoint

The low P/B ratio may indicate underlying issues or overhangs that could suppress stock performance; caution is advised.

Key entities

  • CVS Health Corporation

    A leading healthcare and retail pharmacy chain.

  • Pineapple Energy Inc. (PSFE)

    A provider of renewable energy solutions.

  • Cohen & Steers, Inc. (CNC)

    An investment management firm.

  • Office Depot, Inc. (ODP)

    A retailer of office supplies and services.

  • HCSG

    Healthcare Services Group, Inc.

Related articles

$CVSMedAI 8/10

CVS profit outlook overshadows strong quarter, shares fall

CVS Health reported a better-than-expected Q2 profit of $2.58 per share, beating estimates by 73 cents. However, its updated 2026 EPS forecast rose to $7.90 to $8.10 and it set 2027 EPS at at least $8.44, which some investors viewed as light. Shares fell about 6% to $98.39. CVS also said Caremark may see client losses in 2027.

$CVSMed

Healthcare giant slashes key consultation fee to beat rivals

CVS Health cut the cash price of MinuteClinic online weight-loss consultations to $29 from Aug. 5, with no membership or monthly fee, and said the visit is the entry point for GLP-1 evaluations. The company also reported adjusted EPS of $2.58 on revenue of $106.1B and raised full-year guidance to $7.90-$8.10. CVS shares fell after a Caremark membership decline warning.

$CVSMed

CVS outlook revised to positive by Moody’s on turnaround

Moody’s revised CVS Health’s (NYSE:CVS) outlook to positive from stable, while affirming its Baa3 senior unsecured, Ba1 junior subordinated, and Prime-3 commercial paper ratings. Moody’s cited progress in CVS’s health insurance turnaround and lower leverage, estimating gross debt-to-EBITDA about 3.7x as of June 30, 2026. Total revenues were $415B for the 12 months ended June 30, 2026.